子代供者移植较年长同胞供者改善老年白血病患者生存
该多中心研究纳入185例≥50岁首次完全缓解的急性白血病患者,接受子代(n=62)或HLA相合同胞供者(MSD,n=123)造血干细胞移植,并进行1:1匹配分析(54对)。
要点
- ≥50岁急性白血病首次完全缓解患者,子代供者移植较年长MSD移植总生存更优。
- 子代移植3年移植相关死亡率显著低于MSD(9% vs. 26%)。
- 子代移植3年无白血病生存显著高于MSD(85% vs. 56%)。
核心结论
- 对于>50岁急性白血病患者,子代供者可能优于年长HLA相合同胞供者,非HLA供者特征如亲缘关系和供者年龄比HLA差异更主要影响生存。
研究设计与样本
- 多中心扩展数据集,纳入185例≥50岁首次完全缓解的急性白血病患者,接受子代(n=62)或MSD(n=123)造血干细胞移植,进行1:1匹配配对分析,成功匹配54对子代与54例MSD患者。
临床怎么用
- 对于>50岁接受造血干细胞移植的急性白血病患者,供者选择时可优先考虑年轻子代供者而非年长HLA相合同胞供者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Donor selection for older leukaemia patients undergoing haematopoietic cell transplant (HCT) is not well defined: outcomes might be improved with a younger offspring donor rather than an older human leukocyte antigen (HLA)-matched sibling donor (MSD). We extended our multicentre dataset. A total of 185 acute leukaemia patients (≥ 50 years) transplanted in first complete remission who received HCT from offspring (n = 62) or MSD (n = 123) were included. A 1:1 ratio matched-pair analysis was performed. We were able to match 54 offspring with 54 MSD patients. Outcomes were compared between the two matched-pair groups. The cumulative incidence of grade II/IV acute graft-versus-host disease (GVHD) (26% vs. 35%; P = 0·23) and chronic GVHD (37% vs. 24%; P = 0·19) was comparable between groups (MSD vs. offspring). The lower three-year transplant-related mortality (9% vs. 26%; P = 0·023) and relapse incidence (6% vs. 17%; P = 0·066) resulted in higher overall survival (85% vs. 58%; P = 0·003) and leukaemia-free survival (LFS) (85% vs. 56%; P = 0·001) in offspring HCT compared with that in MSD HCT. These data might favour a young offspring over an older MSD in patients >50 years. The current analyses confirm that non-HLA donor characteristics, such as kinship and donor age, rather than HLA disparity, predominantly influence survival in older acute leukaemia patients.
引用
- Wang Y, Liu QF, Wu DP, et al. Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients. Br J Haematol. 2019. PMID: 31696939. doi:10.1111/bjh.16303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。